Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LBX Pharmacy Chain Joint Stock Company (603883.SS)
CNY12.33
+0.39 (+3.27%)
CN SHH Healthcare Medical - Pharmaceuticals
Address
No. 1 (Xingsha) Kaiyuanxi Road
Changsha, CN
Changsha, CN
CEO
Li Wang
Website
lbxdrugs.com
IPO
2015-04-23
ISIN CNE1000023Q8
Description
LBX Pharmacy Chain Joint Stock Company, headquartered in Changsha, China, oversees a substantial network of retail pharmacies throughout the country. Its operations span 21 distinct provincial markets across China, encompassing regions such as Hunan, Jiangsu, Gansu, Shaanxi, Guangxi, Anhui, Zhejiang, Inner Mongolia, Hubei, Tianjin, Henan, Shanghai, Shandong, Guangdong, Hebei, Beijing, Jiangxi, Ningxia, Sichuan, Fujian, and Guizhou. The company, which commenced operations in 2001, was originally incorporated under the name Laobaixing Pharmacy Chain Joint Stock Company.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY12.33
+0.39 (+3.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.54
Float Shares
375.96M
Free Float %
49.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.49% | +0.16% | -12.43% | -18.05% | -22.99% | -17.16% | -36.28% | -51.58% | -63.90% | -35.81% | +22.72% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
12.33
DCF (Unlevered)
151.51
+1,128.8%
DCF (Levered)
120.23
+875.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.93
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-0.5% Q1'26: +0.8% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-26.5% Q1'26: +6.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+10.4% ★ Q1'26: +15.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.0% Q1'26: +7.5% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+7.9% ★ Q1'26: +17.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.1% Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.44× Q1'26: 1.82× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 12 EPS Ana. |
Dec 2027 12 Rev. Ana. 12 EPS Ana. |
Dec 2028 11 Rev. Ana. 11 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.57B
est: 4.76B (-4.1%)
|
6.09B
est: 5.80B (+5.0%)
|
7.50B
est: 7.64B (-1.8%)
|
9.47B
est: 9.45B (+0.3%)
|
11.66B
est: 11.83B (-1.4%)
|
13.97B
est: 13.97B (0.0%)
|
15.70B
est: 15.69B (+0.1%)
|
20.18B
est: 19.04B (+6.0%)
|
22.44B
est: 22.57B (-0.6%)
|
22.36B
est: 23.01B (-2.8%)
|
22.24B
est: 22.50B (-1.2%)
|
23.69B
22.80B – 25.57B
+5.3% YoY
|
25.65B
23.89B – 29.35B
+8.3% YoY
|
27.93B
27.79B – 28.07B
+8.9% YoY
|
35.82B
33.90B – 39.88B
+28.2% YoY
|
| EBITDA |
395.82M
est: 341.50M (+15.9%)
|
495.12M
est: 416.14M (+19.0%)
|
577.06M
est: 547.58M (+5.4%)
|
730.52M
est: 677.31M (+7.9%)
|
883.62M
est: 848.47M (+4.1%)
|
1.04B
est: 1.00B (+3.5%)
|
1.16B
est: 1.12B (+3.3%)
|
1.53B
est: 1.36B (+12.3%)
|
1.66B
est: 2.86B (-41.8%)
|
1.34B
est: 2.91B (-53.9%)
|
2.32B
est: 2.85B (-18.4%)
|
3.00B
2.89B – 3.24B
+5.3% YoY
|
3.25B
3.03B – 3.72B
+8.3% YoY
|
3.54B
3.52B – 3.56B
+8.9% YoY
|
4.54B
4.29B – 5.05B
+28.2% YoY
|
| EBIT |
356.80M
est: 302.09M (+18.1%)
|
447.94M
est: 368.12M (+21.7%)
|
522.67M
est: 484.40M (+7.9%)
|
658.73M
est: 599.16M (+9.9%)
|
788.55M
est: 750.57M (+5.1%)
|
924.58M
est: 886.23M (+4.3%)
|
1.03B
est: 994.92M (+3.2%)
|
1.37B
est: 1.21B (+13.6%)
|
1.47B
est: 1.31B (+11.9%)
|
1.16B
est: 1.34B (-13.0%)
|
886.44M
est: 1.31B (-32.3%)
|
1.38B
1.33B – 1.49B
+5.3% YoY
|
1.49B
1.39B – 1.71B
+8.3% YoY
|
1.62B
1.62B – 1.63B
+8.9% YoY
|
2.08B
1.97B – 2.32B
+28.2% YoY
|
| Net Income |
240.50M
est: 291.97M (-17.6%)
|
296.90M
est: 356.50M (-16.7%)
|
370.80M
est: 459.42M (-19.3%)
|
435.04M
est: 507.32M (-14.2%)
|
508.71M
est: 607.61M (-16.3%)
|
621.09M
est: 691.98M (-10.2%)
|
669.24M
est: 747.33M (-10.4%)
|
784.96M
est: 841.71M (-6.7%)
|
929.02M
est: 918.48M (+1.1%)
|
519.06M
est: 843.46M (-38.5%)
|
381.85M
est: 737.07M (-48.2%)
|
659.16M
437.79M – 852.47M
-10.6% YoY
|
778.44M
499.63M – 1.15B
+18.1% YoY
|
914.82M
551.38M – 1.49B
+17.5% YoY
|
1.29B
1.20B – 1.48B
+41.5% YoY
|
| SGA |
955.83M
est: 1.16B (-17.7%)
|
1.22B
est: 1.41B (-14.0%)
|
1.54B
est: 1.86B (-17.3%)
|
1.92B
est: 2.30B (-16.7%)
|
2.24B
est: 2.88B (-22.2%)
|
2.55B
est: 3.41B (-25.1%)
|
3.99B
est: 3.82B (+4.3%)
|
5.01B
est: 4.64B (+7.9%)
|
5.75B
est: 5.10B (+12.8%)
|
6.21B
est: 5.20B (+19.3%)
|
2.08B
est: 5.09B (-59.1%)
|
5.35B
5.15B – 5.78B
+5.3% YoY
|
5.79B
5.40B – 6.63B
+8.3% YoY
|
6.31B
6.28B – 6.34B
+8.9% YoY
|
8.09B
7.66B – 9.01B
+28.2% YoY
|
| EPS |
0.54
est: 0.38 (+41.2%)
|
0.61
est: 0.47 (+30.6%)
|
0.76
est: 0.60 (+26.3%)
|
0.84
est: 0.66 (+26.4%)
|
0.98
est: 0.80 (+23.1%)
|
1.18
est: 0.91 (+30.2%)
|
1.26
est: 0.98 (+28.7%)
|
1.05
est: 1.07 (-1.5%)
|
1.23
est: 1.20 (+2.2%)
|
0.68
est: 1.06 (-36.0%)
|
0.50
est: 0.93 (-46.2%)
|
0.82
0.57 – 1.12
-12.2% YoY
|
0.96
0.65 – 1.50
+17.4% YoY
|
1.11
0.72 – 1.95
+16.3% YoY
|
1.69
1.58 – 1.94
+52.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.98B
OE per share TTM
3.93
Owner's Yield
32.20%
Maintenance CapEx ratio
11.04%
Maint CapEx / Avg PPE
17.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 18.8K | 0.44% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 218.0K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 113.1K | 0.29% |
| 4 | Vanguard International High Dividend Yield ETF VYMI | 0.00% | 188.7K | 0.07% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 102.8K | 0.28% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 26.2K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.6K | 0.48% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 104.8K | 0.06% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.29M | 0.06% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 23.4K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
22.1K
Shares Outstanding
758.89M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huan Lin | Vice President | — | female |
| Li Wang | President | — | female |
| Lishan Chen | Chief Financial Officer & Head of Finance | — | male |
| Shi Lei | Head of Accounting | — | — |
| Shini Feng | Board Secretary | — | female |
| Shiyong Su | Vice President | — | male |
| Wenshuai Zhang | Vice President | — | male |
| Xian Dang | Vice President | — | female |
| Xiao Wei Guo | Vice President | — | male |
| Xin Wan | Vice President | — | male |
| Yufei Jiang | Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603883.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
